

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

**WEB OF SCIENCE™**

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Molecular Epidemiology of *Helicobacter pylori* in Brazilian Patients with Early Gastric Cancer and a Review to Understand the Prognosis of the Disease

Bruna Maria Roesler and
José Murilo Robilotta Zeitune

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/58328>

1. Introduction

Helicobacter pylori (*H. pylori*) is an universally distributed bacterium that affects more than half of the world population and is considered an important public health problem. Although colonization with *H. pylori* is not actually a disease, it is a condition that affects the relative risk of developing various clinical disorders of the upper gastrointestinal tract, as chronic gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue (MALT lymphoma) and gastric adenocarcinoma, and, possibly, extradigestive diseases.

Colonization with *H. pylori* virtually leads to infiltration of the gastric mucosa in both antrum and corpus with neutrophilic and mononuclear cells. Gastritis can be classified as an acute or chronic gastritis and it can involve all parts of the stomach or just the fundus, corpus or antrum. The chronic active gastritis is the primary condition related to *H. pylori* colonization, and other *H. pylori*-associated disorders, in particular, resulting from this chronic inflammatory process, as atrophic gastritis, causing an elevated risk of gastric cancer. Considering this association, in 1994 the bacterium was classified as a group I carcinogen by the International Agency for Research on Cancer, World Health Organization.

Molecular techniques have revealed that *H. pylori* possesses a remarkable degree of genetic diversity, which could be responsible for its adaptation in the host stomach and for its pathological characteristics, in addition to the clinical outcome of the infection, although this aspect remains unclear.

In Brazil, it is estimated that only about 10 to 15% of the gastric cancer cases are diagnosed at an early stage, aspect that directly impact the prognosis of the disease, which presents low

survival rates. Unlike patients with advanced gastric cancer, that ones diagnosed at the early stage of the disease present an excellent prognostic, in which a five-year survival rate is more than 90%.

Many early gastric cancers are believed to go through a life cycle consisting of ulcerations, followed by healing, then reulceration, and some tumors remain at this early stage for years even without treatment. Nevertheless, some of these tumors rapidly advanced, perhaps one of the principal questions concerning the gastric carcinogenesis.

Consequently, some questions can be considered about it. Is the *H. pylori* presence important for the evolution of the early lesions in advanced ones? To what extent *H. pylori* eradication could prevent the progression of lesions from one to another stage? Are the genetic characteristics of *H. pylori* strain that is colonizing the patient with early gastric cancer important for the progression of the disease in a faster or in a slower way?

The principal aim of our book chapter is to identify the genetic characteristics of *H. pylori* strains in Brazilian patients diagnosed with early distal type intestinal gastric adenocarcinoma, trying to determine the genotypic pattern of bacterium in our population through molecular techniques. Besides, other aim of our study is to discuss the principal aspects of the *H. pylori* infection and then correlate them with the development of the precancerous lesions and the development of the early gastric cancer properly, trying to understand to what extent the microorganism eradication treatment could be important to preventing the disease progression.

2. *Helicobacter pylori*

2.1. General characteristics

Helicobacter pylori (*H. pylori*) is a spiral-shaped Gram-negative flagellate bacterium that colonizes the human stomach and can establish a long-term infection of the gastric mucosa [1]. In gastric biopsy specimens, *H. pylori* organisms are 2.5 to 5.0 μm long and 0.5 to 1.0 μm wide, with four to six unipolar sheathed flagella, which are essential for bacterial motility. When cultured on solid medium, the bacteria assume a rod-like shape and spiral shapes are infrequent or absent [2]; after prolonged culture on solid or liquid medium, coccoid forms, that are metabolically active, typically predominate [3].

Gastric colonization with *H. pylori* affects at least half the world's population, and, while the infection is on a fast decline in most of the western countries, mainly due to the success of therapeutic regimens and improved personal and community hygiene that prevents re-infection, the situation is exactly opposite in many of the developing countries due to failure of treatment and emergence of drug resistance [4,5]. Most studies suggest that males and females are infected at approximately the same rates [6] and, probably, the infection occurs in the childhood. In developed countries, persons of higher socioeconomic status have lower infection rates, although among certain ethnic minorities, high rates persist despite economic advancement [7].

The routes of transmission of *H. pylori* still remain unclear. Person-to-person transmission and intrafamilial spread seem to be the main route, based on the intrafamilial clustering observed in some studies [8,9]. Children are often infected by a strain which a genetic fingerprint identical to that of their parents, and they maintain this genotype even after moving to a different environment [10]. Animals harbor organisms that resemble *H. pylori*, but with the exception of nonhuman primates [11] and, under particular circumstances, perhaps cats [12] and houseflies (*Musca domestica*) [13], none harbor *H. pylori*. In the same way, food-borne transmission has not been substantiated [14]. Nevertheless, the waterborne infection remains possible [15,16].

H. pylori remains one of the most common worldwide human infections and its isolation by Marshall and Warren (1984) [17] has markedly improved our understanding about the nature of chronic gastritis and other important upper gastrointestinal disorders, such as peptic ulcer disease, mucosa-associated lymphoid tissue (MALT) lymphoma and gastric adenocarcinoma [18]. In 1994, the bacterium was classified as a group I carcinogen by the International Agency for Research on Cancer and is regarded as a primary factor for gastric cancer development [19]. For their revolutionary discovery, Marshall and Warren received the Nobel Prize in Physiology or Medicine in 2005.

In addition, in the last years, *H. pylori* infection has also been associated with some extradi-gestive diseases, such as iron-deficiency anemia [20], idiopathic thrombocytopenic purpura [21,22], cardiovascular diseases [23,24], hepatobiliary diseases [25,26], and diabetes mellitus [27], among others.

2.2. Virulence factors of *H. Pylori*

H. pylori populations are highly diverse and constantly change their genome, which can be an important factor in its adaptation to the host stomach and also for the clinical outcome of the infection. The changes in its genome occur mainly due to point mutations, substitutions, insertions, and/or deletions of their genome. Moreover, mixed infections are frequent and lead to exchange of DNA fragments between different *H. pylori* strains in a single host [28,29]. Experience with other bacterial pathogens suggests that *H. pylori*-specific factors may exist that influence the microorganism pathogenicity, and, these factors, together with the host genetic characteristics and the external environment, can contribute to the clinical outcome of the infection. Among the most studied virulence factors of *H. pylori* are the urease gene, the vacuolating cytotoxin gene (*vacA*), the cytotoxin associated gene-Pathogenicity Island (*cagPAI*) and the duodenal ulcer promoting gene (*dupA*).

Urease is an important enzyme which is produced by *H. pylori* to counteract the acidic environment of the stomach. Urease causes damage to the epithelium through the production of ammonia, that, in conjunction with neutrophil metabolites, forms carcinogenic agents that might participate in the development of gastric malignances [30,31]. Ammonia is capable to cause different cell alterations, including swelling of intracellular acidic compartments, alterations of vesicular membrane transport, repression of protein synthesis and ATP production, and cell-cycle arrest [32]. Urease might also help to the recruitment of neutrophils and monocytes in the mucosa and to the production of proinflammatory cytokines

[33]. It has been demonstrated that this enzyme plays an important role in the *H. pylori* colonization, being observed that urease-defective bacteria mutants are not able to colonize the gastric environment [32].

VacA is a cytotoxin secreted from *H. pylori* as a large 140kd polypeptide and latter trimmed at both ends to finally deliver it in an active form to host cells, where it exerts its activity [34]. The gene encoding VacA is present in all *H. pylori* strains and displays allelic diversity in three main regions: s (signal), i (intermediate) and m (middle); consequently, the activity of the toxin varies between strains [35]. Different combinations of two major alleles of each region (s1, s2, i1, i2, m1, m2) may exist, which results in VacA toxins with distinct capability of inducing vacuolating in epithelial cells [36]. VacA induces multiple cellular activities, including the alteration in the endosomal maturation which consequently leads to vacuolating of epithelial cells, the induction of membrane-channel formation, the cytochrome c releasing from mitochondria and the binding to cell-membrane receptors activating a proinflammatory response [35].

The *cagPAI* is a 40kb region of chromosomal DNA encoding approximately 31 genes that forms a type IV secretion system that forms a pilus that delivers CagA, an oncoprotein, into the cytosol of gastric epithelial cells through a rigid needle structure covered by CagY, a VirB10-homologous protein and CagT, a VirB7-homologous protein, at the base [37,38]. *cagA* is a polymorphic gene that presents different numbers of repeat sequences located in its 3' region and each repeat region of the CagA protein contains Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs, including a tyrosine phosphorylation site [39]. Upon delivery into host cells, CagA undergoes Src-dependent tyrosine phosphorylation and activates an eukaryotic phosphatase (SHP-2), leading to dephosphorylation of host cell proteins and cellular morphologic changes [40]. CagA has also been shown to dysregulate β -catenin signaling [41] and apical-junctional complexes [42], events that have been linked to increased cell motility and oncogenic transformation in a variety of models [43]. In addition, some studies have been reported that the *cagPAI* appears to be involved in the induction of gastric interleukin-8 (IL-8) production, a potent neutrophil-activating chemokine [44]. Consequently, the presence of the *cagA* gene has been associated with higher grades of inflammation, which may lead to the development of the most severe gastrointestinal diseases, such as peptic ulcer disease and gastric cancer [45-48].

H. pylori duodenal ulcer promoting gene (*dupA*), located in the plasticity region of bacterium genome, has been initially described as a risk marker for duodenal ulcer development and a protective factor against gastric cancer [49]. It was the first putative specific marker whose association was described using strains obtained from in both Asian (Japan and Korea) and Western (Colombia) regions and it is thought to be a *virB4* homologue [49, 50]. *dupA* gene encompasses two continuous sequences, *jhp0917* and *jhp0918*, as described in strain J99. The *jhp0917* gene encodes a protein of 475 amino acids, but lacks a region homologous to the C-terminus of *virB4*, while *jhp0918* gene encodes a product of 140 amino acids that is homologous to the missing *virB4* region [51]. Since its discovery, *dupA* gene has been studied by various authors, and the results of their researches suggest that, in some places, *dupA* gene is not associated with an specific disease [52], or it is suggested that it can be associated with gastric cancer development [53-55], or it is directly associated with the development of duodenal ulcer

disease [50,56]. Considering all these results, it is suggested that there must be diversity in gene content that can contribute to bacterial adaptation to genetically different ethnic groups that make up the human population [57].

3. Gastric cancer

3.1. Epidemiology

Cancer is a worldwide full-scale problem as it will affect one in three men and one in four women during their lifetime [58]. Nowadays, this disease represents one in eight deaths around the world. The global cancer rate has doubled in the last 30 years of the 20th century, and will almost triple by 2030, a year in which it is foreseen that 20.3 million people will be diagnosed cancer and 13.2 million will die as a result of this disease [59].

World Health Organization estimates that 43% of cancer deaths are due to tobacco, diet and infection. One-fifth of cancers worldwide are due to chronic infections, mainly from hepatitis viruses (liver), papillomaviruses (cervix), *H. pylori* (stomach), schistosomes (bladder), the liver fluke (bile duct), and human immunodeficiency virus (Kaposi sarcoma and lymphoma) [60].

Gastric cancer continues to be a major global health problem [61] and, despite the decreasing incidence and mortality rates observed worldwide over the last 50 years, it still ranks as a leading cause of cancer-related deaths in many parts of the world [62]. As symptoms are often absent or nonspecific in patients with the early stages of the disease, gastric cancer is usually diagnosed in an advanced stage, when curative options are limited. With exceptions in countries that have developed screening programs for early diagnoses, as example Japan, most patients reach treatment with cancers already in advanced stages [63]. Consequently, gastric cancer carries a poor prognosis, with an overall five-year survival rate of less than 20% [64].

Besides, one study assessed the survival of gastric cancer in population-based registries obtained in cities from four continents and concluded that the large differences observed among these areas were exclusively due to the different types of stomach cancer, highlighting the importance of the stage of the disease as an indicator of the effect of delayed diagnosis on the prognosis of these patients [65].

In Brazil, in 2005, the highest incidence rates, adjusted by age, were found in São Paulo (male, 38,8/100.000; female, 15,0/100.000) and the Federal District (male, 32,7/100.000; female 14,7/100.000) [66]. The National Institute of Cancer in Brazil estimates that, in 2014, there will occur 580.000 new cases of cancer. The most frequent cancers in Brazilian population will be non-melanoma skin (182.000), prostate (69.000), breast (57.000), colon and rectum (33.000), lung (27.000) and stomach (20.000). Considering Brazilian regions and gender, gastric cancer will be the fourth most common cancer in Brazil. In male gender, it is the second most common tumour in the North (11/100.000 cases) and Northeast (10/100.000 cases) regions; it is the fourth most common tumour in the Midwest (11/100.000 cases) and in the South (16/100.000) regions and the fifth most common in the Southeast region (15/100.000 cases). Concerning the female gender, gastric cancer is the fifth most common cancer in Brazil, the third most frequent in the

North region (6/100.000 cases), and the fifth most frequent in the Northeast (6/100.000 cases) and Southeast (8/100.000 cases) regions [67].

The chances of surviving the onset of some common cancers depend largely on how early they are detected and how well they are treated. Early detection is based on the observation that treatment is more effective when cancer is detected early. It includes awareness of early signs and symptoms of cancer and screening, which is the mass testing of people who appear to be healthy. In many developing countries, where these are not feasible, several other low technology approaches are being studied and look promising. The success of public health programmes in detecting cancer early depends on the allocation of resources, availability of qualified specialists and access to follow-up treatment [60].

3.2. Classification of gastric cancer

The vast majority of gastric cancers are adenocarcinomas. Two histologically distinct variants of gastric adenocarcinoma have been described, each with different pathophysiological features: the diffuse type and the intestinal type [68], which corresponds, respectively, to the undifferentiated or poorly-differentiated type and to the well-differentiated type, in the Japanese classification [69].

Diffuse type gastric adenocarcinoma is often associated with familial distribution and more commonly affects younger people. It consists of individually infiltrating neoplastic cells that do not form glandular structures and arises closer to the advancing border of inflammation but without any identifiable histological precursor lesion [62,70,71].

Gastric adenocarcinoma of the intestinal type is preceded by a prolonged precancerous process. In 1975, Correa and colleagues proposed a model of gastric carcinogenesis, postulating that the intestinal type of gastric cancer was the end result of progressive changes in the gastric mucosa, starting with chronic gastritis, followed by multifocal atrophic gastritis and intestinal metaplasia [72]. This model was updated in 1988 and 1992 [73,74] and the following steps were recognized: normal gastric mucosa → superficial gastritis (later renamed non-atrophic gastritis) → multifocal atrophic gastritis without intestinal metaplasia → intestinal metaplasia of the complete (small intestine) type → intestinal metaplasia of the incomplete (colonic) type → low-grade dysplasia (low-grade noninvasive dysplasia) → high-grade dysplasia (high-grade noninvasive dysplasia) → invasive adenocarcinoma [75]. These lesions are well-characterized histopathologically and represent a continuum of changes depicting multiple events that increase in intensity and extension with time [76].

Both diffuse and intestinal types are associated with *H. pylori* infection, which plays an initiating role in the pathogenesis of gastric cancer by changing many important factors, including antioxidant agents, reactive oxygen metabolites, and the balance between epithelial cell proliferation and apoptosis [77]. *H. pylori* infection induces cell apoptosis, stimulates cell proliferation in the gastric epithelium, and causes alterations or mutations of apoptosis/proliferation-related genes [78].

3.3. *Helicobacter pylori* and gastric cancer — The precancerous cascade

Exposure of gastric epithelial cells to *H. pylori* results in an inflammatory reaction with the production of reactive oxygen species and nitric oxide that, in turn, deaminates DNA causing mutations [62]. The complex interplay among *H. pylori* strain, inflammation and host characteristics, besides the external environment, may directly promote diffuse type gastric cancer or induce the cascade of morphological events that leads to intestinal type gastric cancer.

Specifically regarding to intestinal type gastric adenocarcinoma, evidence that *H. pylori* increases the risk of gastric cancer development via the sequence of atrophy and metaplasia originates from various studies, in which it was shown that *H. pylori* positive subjects develop these conditions more often than do uninfected controls [79]. Consequently, since *H. pylori* isolation, many investigators have emphasized its role in gastric carcinogenesis [80,81]. Epidemiological studies have determined that the attributable risk for gastric cancer conferred by *H. pylori* is approximately 75% [82]. Besides, in respect to localization in the stomach, premalignant lesions are most frequently localized in the antrum in the transitional zone between the antrum and corpus [83].

As explained before, Correa and colleagues (1975) proposed a model of gastric carcinogenesis, considering that the intestinal type gastric cancer probably is the result of histological continuum changes that occur especially due to *H. pylori* infection: chronic active nonatrophic gastritis, multifocal atrophic gastritis, intestinal metaplasia, dysplasia, and, finally, invasive adenocarcinoma. Consequently, the principal characteristics of each one of these stages are report below.

3.3.1. *Chronic active non-atrophic gastritis*

Gastritis is characterized by increased infiltration of the lamina propria with mononuclear leukocytes (chronic inflammation) and polymorphonuclear neutrophils (acute inflammation). Additionally, scattered eosinophils and mast cells can be observed. The gastritis is called “active” when polymorphonuclear neutrophils are found, representing acute inflammation. This phase of the precancerous process does not show loss of glands (atrophy) and is called “nonatrophic gastritis” in the updated Sydney classification of gastritis, adopted by most pathologists (Figure 1) [84].

The most frequent cause of gastritis is *H. pylori* infection and the severity of inflammation may vary according to the infected *H. pylori* strain [75].


3.3.2. *Multifocal atrophic gastritis*

Loss of normal glandular tissue is the first specific recognizable step in the precancerous cascade. Usually it is the result of a prolonged inflammatory process and tends to be multifocal, giving rise to the so-called multifocal atrophic gastritis (Figure 2). The foci of atrophy are present in the mucosa of gastric antrum and body, and their extension progresses with time [75]. More virulent bacterial strains and a permissive host immune response are strongly associated with atrophy and progression to severe disease [84].



(Copyright © Center of Diagnosis of Digestive Diseases, State University of Campinas, SP, Brazil. All rights reserved)

Figure 1. Chronic gastritis




(Copyright © Center of Diagnosis of Digestive Diseases, State University of Campinas, SP, Brazil. All rights reserved)

Figure 2. Atrophic gastritis

3.3.3. *Intestinal metaplasia*

At this stage of the gastric precancerous process, the original glands and the foveolar epithelium are replaced by cells with intestinal phenotype [84]. Intestinal metaplasia (Figure 3) is considered to be an advanced stage of atrophy because the metaplastic glands replace the original glands and chronologically the metaplastic glands appear after the gastric glands are lost. Intestinal metaplasia has been classified on the basis of morphology and enzyme histochemistry in two main types: the small intestine or complete type, and the colonic or incomplete type [75].

Up to this point in the cascade, the epithelium in the atrophic and metaplastic lesions remains well differentiated, with normal nuclear-cytoplasmic ratio, normal nuclear morphology, and normal tissue architecture. The dynamics of the precancerous process to this point shows a gradual phenotypic transformation from normal epithelium to metaplastic cells with small intestinal morphology and then to cells resembling colonic mucosa, additionally expressing gastric and colonic mucins. This process usually takes decades and is progressive, supporting the notion that although environmental alterations (bacterial factors and cytokine environment, loss of cell signaling) may have initially driven differentiation decisions, with time, permanent changes in the stem cell compartment have occurred. In some patients with incomplete metaplasia, a mild degree of nuclear atypia and architectural distortion is observed, leading some investigators to consider incomplete metaplasia as a mild form of dysplasia [84,85].



(Copyright © www.gastrolab.net/pawelcom.htm. All rights reserved)

Figure 3. Intestinal metaplasia (antrum)

3.3.4. *Dysplasia*

Also called intraepithelial neoplasia or noninvasive neoplasia, dysplasia is characterized by a neoplastic phenotype, both in terms of cell morphology and architectural organization [75]. The nuclei of the dysplastic epithelium are enlarged, hyperchromatic, irregular in shape, and devoid of polarity [84]. The Padova classification is focused on gastric dysplasia and was developed by an international group of experienced gastrointestinal pathologists and recognizes five categories of lesions, utilizing mostly western nomenclature and grouping them numerically following the prevailing Japanese system: 1. negative for dysplasia; 2. indefinite for dysplasia; 3. noninvasive neoplasia (sub-classified in low grade or high grade); 4. suspicious for invasive carcinoma; and 5. invasive carcinoma [86].

The management of low-grade dysplasia is not well defined and there is a recommendation of annual endoscopic monitoring with rebiopsy [87]. Nevertheless, patients with high-grade dysplasia confirmed at least two gastrointestinal pathologists should undergo surgical or endoscopic resection because of the high probability of coexisting or metachronous invasive carcinoma [88].

3.3.5. *Invasive adenocarcinoma*

Invasive adenocarcinoma is the next stage in the cascade and requires the penetration of neoplastic cells into the surrounding stroma (Figure 4). Recent evidence suggests that this step demands that neoplastic cells acquire the capability of degrading the stromal matrix surrounding the neoplastic cells [75].



(Copyright © Center of Diagnosis of Digestive Diseases, State University of Campinas, SP, Brazil. All rights reserved)

Figure 4. Gastric adenocarcinoma

3.4. Early and advanced lesions

Follow-up of patients with precursor lesions in populations at high gastric cancer risk has thrown light on the dynamics of the process. The progression of the precursor lesions described before follows a pattern of steady state, with episodes of progression to more advanced lesions and episodes of regression to less advanced lesions.

Unlike patients with advanced gastric cancer, patients diagnosed in an early stage of the disease present an excellent prognostic, in which a five-year survival rate is more than 90%. Early gastric cancer lesions are defined as the adenocarcinoma that is confined to the mucosa or submucosa, irrespective of lymphonode invasion (Figure 5). Many early gastric cancers are believed to go through a life cycle consisting of ulcerations, followed by healing, then reulceration, and some lesions remain at this early stage for years even without treatment [89]. Nevertheless, some early tumours rapidly became advanced and it is one of the principal

questions concerning the gastric carcinogenesis. Are *H. pylori* virulence factors important to influence these alterations? To what extent *H. pylori* eradication treatment would be important to prevent the continued progression of the disease? To what extent *H. pylori* eradication in the early stage of cancer would be important to prevent the appearance of new lesions?



(Copyright © Center of Diagnosis of Digestive Diseases, State University of Campinas, SP, Brazil. All rights reserved)

Figure 5. Early gastric adenocarcinoma

Considering these important questions, our chapter is divided into two sections: 1. the identification of the principal genetic characteristics of *H. pylori* strains in Brazilian patients with early distal type intestinal gastric adenocarcinoma, in order to determine the genotypic pattern of bacterium in our population through molecular techniques; 2. the discussion of the principal studies concerning *H. pylori* eradication and its importance to prevent the progression of precancerous lesions and the importance of *H. pylori* eradication in the early gastric cancer to prevent the development of new cancerous lesions.

4. Materials and methods

4.1. Determination of principal genotypes of *H. Pylori* in Brazilian patients with early gastric adenocarcinoma

4.1.1. Clinical samples

Clinical isolates of *H. pylori* analyzed in this study were obtained from the Laboratory of Pathology of the Center of Diagnosis of Digestive Diseases, Faculty of Medical Sciences, State University of Campinas (Campinas, São Paulo, Brazil). Third one paraffin wax-embedded specimens of gastric tissue were analyzed from a total of 31 patients with early distal type intestinal gastric adenocarcinoma. All the gastric tissue samples were obtained from endoscopic biopsy and were positive for *H. pylori* by histological analysis. Samples from gastric tissue obtained from endoscopic biopsy of patients with chronic gastritis and peptic ulcer

disease and positive for *H. pylori* were used as positive controls for all the reactions carried out in this study. The study was approved by the Ethics Committee of the Faculty of Medical Sciences, State University of Campinas.

4.1.2. Methods

Paraffin wax-embedded tissue DNA extraction was carried out with xylene and ethanol washes for paraffin removal; successive steps using proteinase K, phenol, chloroform, and isoamyl alcohol were carried out in order to isolate and purify the DNA [90]. Quantification of the obtained product and polymerase chain reaction (PCR) for human betaglobin gene [91] were carried out to guarantee the quality of all the results.

After DNA extraction, PCR for ureaseC [92], vacA (s and m) [93,94,95], cagA [96], cagT [97] and dupA (jhp0917 and jhp0918) [49] genes were performed. Primers pairs for all the genes as well as the length of the fragments are described in Table 1. PCR for ureaseC gene was carried out to confirm the positivity for *H. pylori* in all the samples.

After amplification, each PCR product was analyzed by eletrophoresis on a 2% agarose gel stained with ethidium bromide with a 0.5 X tris-acetate-EDTA buffer. A 100-bp ladder was used as standard.

Gene	Strand	Primer sequence (5' - 3')	Length (bp)
betaglobin	+	ACAAACTGTGTTCACTAGC	110
	-	CAACTTCATCCACGTTTCACC	
ureaseC	+	AAGCTTTAGGGGTGTTAGGGGTTT	294
	-	AAGCTTACTTTCTAACACTAACGC	
vacA (s1/s2)	+	ATGGAAATACAACAAACACAC	s1: 259
	-	CTGCTTGAATGCGCCAAAC	s2: 286
vacA m1	+	GGTCAAAATGCGGTCATGG	290
	-	CCATTGGTACCTGTAGAAAC	
vacA m2	+	ATGCTTTAATATCGTTGAGA	198
	-	GAACATGTTTTAGTGAAAGC	
cagA	+	GATAACAGGCAAGCTTTTGAGG	349
	-	CTGCAAAAGATTGTTTGGCAGA	
cagT	+	CCATGTTTATACGCCTGTGT	301
	-	CATCACCACACCCTTTTGAT	
dupA (jhp0917)	+	TGGTTTCTACTGACAGAGCGC	307
	-	AACACGCTGACAGGACAATCTCCC	
dupA (jhp0918)	+	CCTATATCGCTAACGCGCGCTC	276
	-	AAGCTGAAGCGTTTGTAACG	

Table 1. Sequence of synthetic oligonucleotide primers used to characterization of *H. pylori* strains

Then, for each specific reaction, products obtained were classified in vacA s1m1, s2m1, s1m2 or s2m2; cagA positive or negative; cagT positive or negative; and dupA positive or negative. dupA gene was considered positive when its two regions (jhp0917 and jhp0918) were positive simultaneously.

After all amplifications, a table with absolute frequencies (n) and percentages (%) was made in order to determine genotypes combinations.

4.2. Analysis of the principal manuscript references concerning the study of eradication treatment of *H. pylori* in precancerous lesions and early gastric cancer

After determination of the principal genotype presented in Brazilian patients with early gastric cancer, a review concerning the importance of eradication of *H. pylori* in precancerous lesions and in early gastric adenocacinoma was done.

5. Results

5.1. Determination of principal genotypes of *H. Pylori* in Brazilian patients with early gastric adenocarcinoma

PCR for ureaseC gene of *H. pylori* was positive for all 31 samples obtained from patients with early distal type intestinal gastric adenocarcinoma. As regards to vacA gene region s, of 31 samples, 71.0% (22 cases) were s1 and 29.0% (9 cases) were s2. Related to the vacA region m, all the samples were m1. Following this analysis, samples were classified in s1m1 or s2m1. So, 71.0% (22 cases) were s1m1 and 29.0% (9 cases) were s2m1.

Classification	
UreaseC	31 (100.0%)
vacA s1	22 (71.0%)
vacA s2	9 (29.0%)
vacA m1	31 (100.0%)
vacA m2	0 (0.0%)
vacA s1m1	22 (71.0%)
vacA s2m1	9 (29.0%)
cagA positive	19 (61.3%)
cagA negative	12 (38.7%)
cagT positive	17 (54.8%)
cagT negative	14 (45.2%)
dupA (jhp0917/jhp0918) positive	11 (35.5%)
dupA (jhp0917/jhp0918) negative	20 (64.5%)
Total	31 (100.0%)

Table 2. Frequencies and percentages of the principal genes of *H. pylori* studied in samples of early gastric cancer

As regards to gene *cagA*, 61.3% (19 cases) were *cagA* positive and, for *cagT* gene, 54.8% (17 cases) were positive. For *dupA* (*jhp0917/jhp0918*) gene, there were 35.5% (11 cases) of positivity. All these results can be seen in Table 2.

Genotypes combinations were then analyzed and the most prevalent genotype for gastric samples obtained from Brazilian patients with early distal type intestinal gastric adenocarcinoma was *vacA* s1m1, *cagA* positive, *cagT* positive and *dupA* negative (Table 3).

Genotype combinations: <i>vacA</i> s/m <i>cagA</i> <i>cagT</i> <i>dupA</i> (<i>jhp0917/jhp0918</i>)	Early gastric cancer
s1m1 neg neg neg	4 (12.90)
s1m1 neg neg pos	1 (3.23)
s2m1 neg neg neg	1 (3.23)
s2m1 neg neg pos	0 (0.00)
s1m1 neg pos neg	2 (6.45)
s1m1 neg pos pos	1 (3.23)
s2m1 neg pos neg	2 (6.45)
s2m1 neg pos pos	1 (3.23)
s1m1 pos neg neg	3 (9.68)
s1m1 pos neg pos	2 (6.45)
s2m1 pos neg neg	2 (6.45)
s2m1 pos neg pos	1 (3.23)
s1m1 pos pos neg	5 (16.13)
s1m1 pos pos pos	4 (12.90)
s2m1 pos pos neg	2 (6.45)
s2m1 pos pos pos	0 (0.00)
Total	31

Table 3. Genotype combinations for early gastric adenocarcinoma samples

5.2. Analysis of the principal manuscript references concerning the study of eradication treatment of *H. pylori* in precancerous lesions and early gastric cancer

Epidemiological studies have established a strong causal relationship between *H. pylori* infection and gastric cancer. *H. pylori* eradication is therefore likely to be one of the most promising approaches to gastric cancer prevention. Animal studies have shown that eradication of *H. pylori* infection, especially at the early stage, is effective in preventing *H. pylori*-related gastric carcinogenesis. However, the available data from human studies show that *H. pylori* eradication does not completely prevent gastric cancer and that it might be useful in patients without atrophic gastritis or intestinal metaplasia at baseline [77].

Considering these important issues, the present chapter book analyzed and discussed some studies that assessed the possible relationship between the eradication of *H. pylori* infection and the prevention of gastric cancer even if the precancerous cascade has started. Obviously,

there should be a point which there is no return in this process and the presence of *H. pylori* could not be more decisive to continue the progression of the precancerous lesions. With the aim to analyze these topics, we discussed some important questions concerning *H. pylori* infection, precancerous cascade and *H. pylori* eradication treatment, both in the precancerous lesions (atrophic gastritis, metaplasia intestinal and dysplasia) and in the early gastric cancer stage.

6. Discussion

Molecular techniques may be applied to the measurement of host or agent factors and of exposures. Molecular techniques help to stratify and to refine data by providing more sensitive and specific measurements, which facilitate epidemiologic activities, including disease surveillance, outbreak investigations, identifying transmission patterns and risk factors among apparently disparate cases, characterizing host-pathogen interactions, detecting uncultivable organisms, providing clues for possible infectious causes of cancer and other chronic diseases, and providing better understanding of disease pathogenesis at the molecular level [98].

Our study determined the principal genotype of *H. pylori* strains in Brazilian patients with early distal type intestinal gastric adenocarcinoma, which is *vacA* s1m1, *cagA* positive, *cagT* positive and *dupA* negative. It provides to the scientific community important information concerning the epidemiology of gastric cancer in Brazil, as regards to the infecting strains. This principal *H. pylori* genotype was also the principal found in advanced gastric cancer samples, but, when considering the *cagA* gene in an isolate evaluation, it was more incident in patients with advanced gastric cancer [48].

Many factors, including a high-salt diet [99], genetic abnormality [100] and autoimmune gastritis [101], among others, have been reported concerning gastric carcinogenesis; however, it is clear that *H. pylori* infection is the most important gastric carcinogen [60, 102].

Currently recommended anti-*H. pylori* infection therapies achieve eradication rates of up to 90% [103]. Several studies have indicated that *H. pylori* screening and eradication is a cost-effective strategy for the prevention of gastric cancer in middle-aged adults, even if the treatment prevents only 20%-30% of *H. pylori*-associated cancers, and that the strategy is particularly beneficial in high-risk populations and in the long term [77,104,105,106], although the feasibility, safety and appropriated timing of this strategy for cancer prevention in the general population remains to be determined [77].

Some studies focused on patients with gastric precancerous lesions such as gastric atrophy, intestinal metaplasia and dysplasia and evaluated the effect of eradicating *H. pylori* on the intermediate lesions in the carcinogenic cascade rather than using gastric cancer as the primary end points [107].

Conflicting results have been reported on whether or not these precancerous lesions were reversible following successful eradication of *H. pylori* infection.

The investigation of Uemura et al. (2001) [108] is considered the first study providing some evidence that *H. pylori* eradication has an impact in gastric cancer. In this study, none of the 253 treated patients developed cancer, whilst there were 36 gastric cancer cases among 993 untreated patients. However, it is of note that the mean duration of follow-up after eradication was significantly shorter than the mean duration for patients who were not treated (4,8 vs. 8,5 years; $p < 0.001$). Therefore, the risk of gastric cancer development could have been understated in the treated group [107].

In a randomized placebo controlled study in China, gastritis (acute and chronic) decreased in both the antrum and the corpus at one year after *H. pylori* eradication and a slight regression of intestinal metaplasia was observed [109]. With similar results, a follow-up study developed by Zhou et al. (2003) [110] demonstrated that *H. pylori* eradication significantly reduced the severity and activity of chronic gastritis. Besides, while the proportion of intestinal metaplasia in the *H. pylori* positive group increased significantly, intestinal metaplasia in the antrum either regressed or had no progression in the *H. pylori* negative group.

In Colombia, a randomized, controlled chemoprevention trial with patients with confirmed multifocal nonmetaplastic atrophy and/or intestinal metaplasia demonstrated that, after *H. pylori* eradication therapy and/or dietary supplementation with ascorbic acid or beta-carotene, or their placebos, it was observed a significant increase in the rate of regression of the precursors lesions [111].

Other follow-up studies also identified that *H. pylori* eradication in patients with intestinal metaplasia could be important in the regression of the lesions [112-118]. In the same way, other randomized studies identified that *H. pylori* eradication in intestinal metaplasia could be important in the regression of this precancerous lesion [76,109-111,119,120]. Oppositely, other trials, both follow-up and randomized control, had not identified regression of intestinal metaplasia when *H. pylori* eradication was administrated [121-129].

Concerning to patients with gastric atrophy, the most part of the studies have identified that this lesion presents a regression when *H. pylori* eradication occurs [76, 109, 111, 119, 120, 128-130]. In Japan, where there is a significant ability in diagnostic, with a detection of 94% of early gastric cancers, one important multicenter randomized controlled trial by the Japan Gast Study Group enrolled patients undergoing previous endoscopic therapy for gastric cancer and demonstrated that eradication therapy significantly reduced the prevalence of secondary gastric cancer in a 3-year follow-up period [131]. However, this study does not demonstrate that eradication therapy can prevent newly developed gastric cancer even in secondary cancer, because the follow-up period was too short.

As well as other authors mentioned before, Ito (2009) [132] considered that theoretically *H. pylori* eradication therapy should be beneficial for cancer prevention. However, attention should be drawn to the fact that the gastric cancer risk is not similar between noninfected and eradicated people. Until now, many human studies have demonstrated that some patients develop gastric cancer even if they have undergone successful eradication therapy [133]. Considering it, we can conclude that eradication therapy may have an effect on cancer prevention if the therapy is administrated before a single cancer cell has transformed or before

cancer tissue shows invasive growth. It is likely that eradication therapy has no effect if the cancer has progressed to an advanced stage.

Wong et al. (2004) [134], with the aim to determine whether eradication of *H. pylori* infection reduces the incidence of gastric cancer, carried out a randomized, placebo controlled trial with 1630 *H. pylori* infected patients in a high-risk region of China. Their results indicated that *H. pylori* eradication can reduce the incidence of gastric cancer in patients without precancerous lesions at entry. Besides, the eradication therapy had no statistically significant effect on the incidence of gastric cancer in patients with precancerous lesions on presentation. It appears that there is a point of no return for patients with precancerous lesions and a chemoprevention strategy may work only in a subset of *H. pylori* infected subjects [135].

As regards to animal models, they are useful because they represent tractable systems that permit insights into the effects of host, pathogen and environmental factors on gastric carcinogenesis [136]. Nevertheless, the use of animals does not completely reflect *H. pylori*-induced cancer in humans. Romero-Gallo et al. (2008) [137], using a population of gerbils that received antibiotics for *H. pylori* treatment, demonstrated that the timing of intervention influences the magnitude of suppression of pro-inflammatory cytokine expression, inflammation, pre-malignant, and neoplastic lesions. These findings have demonstrated that treatment of *H. pylori* decreases the incidence and the severity of pro-inflammatory cytokine expression, as well as premalignant and malignant lesions. However, the effectiveness of eradication is dependent upon the timing of intervention [137].

A 5-year study in Japanese monkeys (*Macaca fustata*) demonstrated that *H. pylori* infection can cause gastric atrophy, increased cell proliferation, and mutation of *p53* in gastric epithelial cells [138]. In other study, with Mongolian gerbils, it was demonstrated that the resulting pathological changes in gastric mucosa are similar to those in humans [139]. Some studies demonstrated that when the animals were infected with *H. pylori* together with a carcinogen (N-methyl-N-nitrosourea or N-methyl-N-nitro-N-nitrosoguanidine), they developed gastric cancer (both diffuse and intestinal types) that were at significantly higher frequencies than animals receiving either *H. pylori* or the carcinogen alone [140-142]. Gastric cancer incidence was reduced at 75 weeks to 6.7%, 27.3%, and 38.2% in Mongolian gerbils receiving eradication treatment at early (15 weeks), middle (35 weeks) and late (55 weeks) stages, respectively. These results suggest that eradication at an early stage might be effective in preventing carcinogenesis. Other study demonstrated that application of antimicrobial therapy at 8 weeks postinoculation of bacterium attenuated inflammation, but did not completely prevent the development of premalignant and malignant lesions, indicating that the *H. pylori* eradication therapy is effective when administered at an early stage after infection [143]. Nevertheless, it is important to remember that the carcinogenic potential of *H. pylori* is strain dependent and some results of these studies could be caused by the use of an *H. pylori* strain that lacked carcinogenic potential.

In the mouse model, both *H. pylori* infection and gastric atrophy increase the serum concentration of polypeptide hormone gastrin, a hormone that controls secretion of gastric acid by the stomach's parietal cells and hypergastrinemia is regarded to play a role in the development.

The results obtained indicated that the timing of antimicrobial eradication therapy is very important as early application can prevent the progression of gastric cancer [144].

Finally, for cancers detected early, endoscopic mucosal resection can conserve the noncancerous gastric mucosa, but it can not eliminate the recurrence of metachronous gastric cancer [145]. Fukase et al. (2008) [131], in a randomized control trial, studied a group of patients submitted to *H. pylori* eradication therapy following endoscopic resection of early gastric cancer. These patients were monitored at different time intervals: at 3 years, metachronous gastric cancer had developed in 9 of 225 patients in the eradication group compared with 24 of 250 patients in the control group, suggesting that prophylactic eradication of *H. pylori* in a high-risk population can substantially reduce gastric cancer rates.

Briefly, the most part of the studies suggests that *H. pylori* eradication is able to induce regression of precancerous lesions in most of the treated subjects, and particularly in those with baseline, early and non-severe lesions. However, it also seems that a proportion of treated subjects will still show progression of preneoplastic lesions. So, we can consider that they really are other factors that contribute to the progression of these lesions. So, *H. pylori* eradication is an effective strategy in reducing the risk of gastric cancer; however, it is not efficient enough to eradicate gastric cancer. Prevention of the infection, *H. pylori* immunization, *H. pylori* eradication in the youth, selection of the high-risk population, and alternative chemopreventive measures may be essential for optimal management of malignancy of the stomach.

7. Conclusions

All the available evidence suggests that *H. pylori* eradication might represent a primary chemopreventive strategy in a subset of subjects. However, *H. pylori* eradication in those patients who have already developed advanced preneoplastic lesions does not prevent gastric cancer development, and endoscopic follow-up should always be performed.

More research is needed to elucidate mechanisms underlying the *H. pylori*-induced gastric carcinogenesis. As the infection usually depends on the characteristics of the infecting strain, studies that determine the genotypes in gastric cancer, as we presented in our study, are necessary. Besides, more trials concerning the interaction among the infecting strain, the host characteristics and the external environment are also needed to explaining the complex gastric carcinogenesis. An understanding of biochemical, genetic and epigenetic changes following eradication therapy would be helpful to develop strategies to identify high-risk individuals, thereby contributing to effective management in gastric cancer prevention.

Finally, it is important to gain more insight into the pathogenesis of *H. pylori*-induced gastric adenocarcinoma, not only to develop more effective treatments for this cancer, but also because it might serve as a paradigm for the role of chronic inflammation in the genesis of other malignancies.

Author details

Bruna Maria Roesler and José Murilo Robilotta Zeitune

*Address all correspondence to: roeslerbruna@gmail.com

Department of Internal Medicine, Center of Diagnosis of Digestive Diseases, Faculty of Medical Sciences – State University of Campinas – UNICAMP, Campinas, São Paulo, Brazil

References

- [1] Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. *Clinical Microbiology Reviews* 2006; 19(3): 449-490.
- [2] Goodwin CS, Armstrong JA. Microbiological aspects of *Helicobacter pylori* (*Campylobacter pylori*). *European Journal of Clinical Microbiology* 1990; 9(1): 1-13.
- [3] Bode G, Mauch F, Malfertheiner P. The coccoid forms of *Helicobacter pylori*. Criteria for their viability. *Epidemiology and Infection* 1993; 111(3): 483-490.
- [4] Blaser MJ. An endangered species in the stomach. *Scientific American* 2005; 292(2): 38-45.
- [5] Ahmed N. 23 years of the discovery of *Helicobacter pylori*: Is the debate over? *Annals of Clinical Microbiology and Antimicrobials* 2005; 4: 17-19.
- [6] Replogle ML, Glaser SL, Hiatt RA, Parsonnet J. Biologic sex as a risk factor for *Helicobacter pylori* infection in healthy young adults. *American Journal of Epidemiology* 1995; 142(8): 856-863.
- [7] Graham DY, Malaty HM, Evans DG, Evans DJ, Klein PD, Adam E. Epidemiology of *Helicobacter pylori* in an asymptomatic population in the United States. *Gastroenterology* 1991; 100(6): 1495-1501.
- [8] Urita Y, Watanabe T, Kawagoe N, Takemoto I, Tanaka H, Kijima S, Kido H, Maeda T, Sugawara Y, Miyazaki T, Honda Y, Nakanishi K, Shimada N, Nakajima H, Sugimoto M, Urita C. Role of infected grandmothers in transmission of *Helicobacter pylori* to children in a Japanese rural town. *Journal of Paediatrics and Child Health* 2013; 49(5): 394-398.
- [9] Bastos J, Carreira H, La Vecchia C, Lunet N. Childcare attendance and *Helicobacter pylori* infection: systematic review and meta-analysis. *European Journal of Cancer Prevention* 2013; 22(4): 311-319.
- [10] Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rapuolli R. *Helicobacter pylori* virulence and genetic geography. *Science* 1998; 284(5418): 1328-1333.

- [11] Dubois A, Fiala N, Heman-Ackah LM, Drazek ES, Tarnawski A, Fishbein WN, Perez-Perez GI, Blaser MJ. Natural gastric infection with *Helicobacter pylori* in monkeys: a model for spiral bacteria infection in humans. *Gastroenterology* 1994; 106(6): 1405-1417.
- [12] Fox JG, Batchelder M, Marini R, Yan L, Handt L, Li X, Shames B, Hayward A, Campbell J, Murphy JC. *Helicobacter pylori*-induced gastritis in the domestic cat. *Infection and Immunity* 1995; 63(7): 2674-2681.
- [13] Grubel P, Hoffman JS, Chong FK, Burstein NA, Mepani C, Cave DR. Vector potential of houseflies (*Musca domestica*) for *Helicobacter pylori*. *Journal of Clinical Microbiology* 1997; 35(6): 1300-1303.
- [14] Dunn BE, Cohen H, Blaser MJ. *Helicobacter pylori*. *Clinical Microbiology Reviews* 1997; 10(4): 720-741.
- [15] Lu Y, Redlinger TE, Avitia R, Galindo A, Goodman K. Isolation and genotyping of *Helicobacter pylori* from untreated municipal wastewater. *Applied and Environmental Microbiology* 2002; 68(3): 1436-1439.
- [16] Bahrami AR, Rahimi E, Ghasemian Safaei H. Detection of *Helicobacter pylori* in City Water, Dental Unit's Water and Bottled Mineral Water in Isfahan, Iran. *Scientific World Journal* 2013.
- [17] Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; 1(8390): 1311-1315.
- [18] Ahmed N, Sechi LA. *Helicobacter pylori* and gastroduodenal pathology. New threats of the old friend. *Annals of Clinical Microbiology and Antimicrobials* 2005; 4:1-10.
- [19] International Agency for Research on Cancer. Schistosomes, liver flukes and *Helicobacter pylori*. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC monographs on the evaluation of carcinogenic risks to humans. World Health Organization, International Agency for Research on Cancer 1994; 61: 1-241.
- [20] Capurso G, Lahner E, Marcheggiano A, Caruana P, Carnuccio A, Bordi C, Delle Fave G, Annibale B. Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anemia associated with *Helicobacter pylori* infection. *Alimentary Pharmacology & Therapeutics* 2001; 15(11): 1753-1761.
- [21] Pelicano R, Franceschi F, Saracco G, Fagoonee S, Roccarina D, Gasbarrini A. *Helicobacters* and extragastric diseases. *Helicobacter* 2009; 14(Suppl 1): 58-68.
- [22] Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, Kelton JG, Crowther MA. Platelet count response to *H. pylori* treatment in patients with immune thrombocytopenic purpura with and without *H. pylori* infection: a systematic review. *Haematologica* 2009; 94(6): 850-856.

- [23] Franceschi F, Navarese EP, Mollo R, Giupponi B, De Marco G, Merra G, Gasbarrini G, Silveri NG. *Helicobacter pylori* and atherosclerosis. A review of the literature. *Recenti Progressi in Medicina* 2009; 100(2): 91-96.
- [24] Rogha M, Nikvarz M, Poumoghaddas Z, Shirneshan K, Dadkhah D, Poumoghaddas M. Is *Helicobacter pylori* infection a risk factor for coronary heart disease? *ARYA Atherosclerosis* 2012; 8(1): 5-8.
- [25] Isaeva GSh, Abuzarova ER, Valeeva IuV, Pozdeev OK, Murav'eva EV. *Helicobacter pylori* in patients with disorders of hepatobiliary system. *Zh Mikrobiol Epidemiol Immunobiol* 2009; 2: 96-101.
- [26] Pirouz T, Zounubi L, Keivani H, Rakhshani N, Hormazdi M. Detection of *Helicobacter pylori* in paraffin-embedded specimens from patients with chronic liver diseases, using the amplification method. *Digestive Diseases and Sciences* 2009; 54(7): 1456-1459.
- [27] Zhou X, Zhang C, Wu J, Zhang G. Association between *Helicobacter pylori* infection and diabetes mellitus: a meta-analysis of observational studies. *Diabetes Research and Clinical Practice* 2013; 99(2): 200-208.
- [28] Blaser MJ, Berg DE. *Helicobacter pylori* genetic diversity and risk of human disease. *The Journal of Clinical Investigation* 2001; 107(7): 767-773.
- [29] Suerbaum S, Michetti P. *Helicobacter pylori* infection. *New England Journal of Medicine* 2002; 347(15): 1175-1186.
- [30] Megraud F, Neman-Simha, Brugmann D. Further evidence of the toxic effect of ammonia produced by *Helicobacter pylori* urease on human epithelial cells. *Infection and Immunity* 1992; 60(5): 1858-1863.
- [31] Suzuki M, Miura S, Suematsu M, Fukumura D, Kurose I, Suzuki H, Kai A, Kudoh Y, Ohashi M, Tsuchiya M. *Helicobacter pylori*-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury. *American Journal of Physiology* 1992; 263 (5 Pt 1): G719-725.
- [32] Montecucco C, Rapuolli R. Living dangerously: how *Helicobacter pylori* survives in the human stomach. *Nature Reviews. Molecular Cell Biology* 2001; 2(6): 457-466.
- [33] Harris PR, Mobley HL, Perez-Perez GI, Blaser MJ, Smith PD. *Helicobacter pylori* urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production. *Gastroenterology* 1996; 111(2): 419-425.
- [34] Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR. Cytotoxic activity in broth-culture filtrates of *Campylobacter pylori*. *Journal of Medical Microbiology* 1988; 26(2): 93-99.
- [35] Amieva MR, El-Omar EM. Host-bacterial interactions in *Helicobacter pylori* infection. *Gastroenterology* 2008; 134(1): 306-323.
- [36] Atherton JC, Cao P, Peek RMJr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*. Association of specific vacA types

- with cytotoxin production and peptic ulceration. *Journal of Biological Chemistry* 1995; 270(30): 17771-17777.
- [37] Covacci A, Rappuoli R. Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. *Journal of Experimental Medicine* 2000; 191(4): 587-592.
- [38] Backert S, Selbach M. Role of type IV secretion in *Helicobacter pylori* pathogenesis. *Cellular Microbiology* 2008; 10(8): 1573-1581.
- [39] Hatakeyama M. Oncogenic mechanisms of the *Helicobacter pylori* CagA protein. *Nature Reviews. Cancer* 2004; 4(9): 688-694.
- [40] Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M. SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA protein. *Science* 2002; 295(5555): 683-686.
- [41] Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM Jr, Azuma T, Hatakeyama M. *Helicobacter pylori* CagA interacts with E-cadherin and deregulates the β -catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. *Oncogene* 2007; 26(32): 4671-4626.
- [42] Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. Disruption of the epithelial apical-junctional complex by *Helicobacter pylori* CagA. *Science* 2003; 300(5624): 1430-1434.
- [43] Suzuki M, Mimuro H, Suzuki T, Park M, Yamamoto T, Sasakawa C. Interaction of CagA with Crk plays an important role in *Helicobacter pylori*-induced loss of gastric epithelial cell adhesion. *Journal of Experimental Medicine* 2005; 202(9): 1235-1247.
- [44] Brandt S, Kwok T, Hartig R, Konig W, Backert S. NF-kappaB activation and potentiation of proinflammatory responses by the *Helicobacter pylori* CagA protein. *Proceedings of the National Academy of Sciences of the United States of America* 2005; 102(26): 9300-9305.
- [45] Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with *Helicobacter pylori* strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. *Cancer Research* 1995; 55(10): 2111-2115.
- [46] Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative *Helicobacter pylori* infection. *Gut* 1997; 40(3): 297-301.
- [47] Figueiredo C, van Doorn LJ, Nogueira C, Soares JM, Pinho C, Figueira P, Quint WG, Carneiro F. *Helicobacter pylori* genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains. *Scandinavian Journal of Gastroenterology* 2001; 36(2): 128-135.

- [48] Roesler BM, Costa SCB, Zeitune JMR. Virulence factors of *Helicobacter pylori* and their relationship with the development of early and advanced distal intestinal type gastric adenocarcinoma. In: Paola Tonino (ed.). Gastritis and gastric cancer. New insights in gastroprotection, diagnosis and treatments. Rijeka: InTech; 2011.
- [49] Lu H, Hsu P, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of *Helicobacter pylori*. *Gastroenterology* 2005; 128(4): 833-848.
- [50] Zhang Z, Zheng Q, Chen X, Xiao S, Liu W, Lu H. The *Helicobacter pylori* duodenal ulcer promoting gene, dupA in China. *BMC Gastroenterology* 2008; 8: 49-54.
- [51] Yamaoka Y. Roles of the plasticity regions of *Helicobacter pylori* in gastroduodenal pathogenesis. *Journal of Medical Microbiology* 2008; 57(5): 545-553.
- [52] Douraghi M, Mohammadi M, Oghalaie A, Abdirad A, Mohagheghi MA, Hosseini ME, Zeraati H, Ghasemi A, Esmaili M, Mohajerani N. dupA as a risk determinant in *Helicobacter pylori* infection. *Journal of Medical Microbiology* 2008; 57 (Pt.5): 554-562.
- [53] Argent RH, Burette A, Miendje Deyi VY, Atherton JC. The presence of dupA in *Helicobacter pylori* is not significantly associated with duodenal ulceration in Belgium, South Africa, China or North America. *Clinical Infectious Diseases* 2007; 45(9): 1204-1206.
- [54] Schimidt HMA, Andres S, Kaakoush NO, Engstrand L, Eriksson L, Goh KL, Fock KM, Hilmi I, Dhamodaran S, Forman D, Mitchell H. The prevalence of the duodenal ulcer promoting gene (dupA) in *Helicobacter pylori* isolates varies by ethnic group and is not universally associated with disease development: a case-control study. *Gut Pathogens* 2009; 1(1): 5-13.
- [55] Roesler BM, Oliveira TB, Costa SCB, Zeitune JMR. Is there any relationship between *Helicobacter pylori* dupA gene and the development of early and advanced gastric cancer in Brazilian patients? *Journal of Medical Research and Science* 2011; 2(1): 15-24.
- [56] Arachchi HSJ, Kalra V, Lal B, Bhatia V, Baba CS, Chakravarthy S, Rohatgi S, Sarma PM, Mishra V, Das B, Ahuja V. Prevalence of duodenal ulcer promoting gene (dupA) of *Helicobacter pylori* in patients with duodenal ulcer in North Indian population. *Helicobacter*. 2007; 12(6): 591-597
- [57] Gressmann H, Linz B, Ghai R, Pleissner KP, Schlapbach R, Yamaoka Y, Kraft C, Suerbaum S, Meyer TF, Achtman M. Gain and loss of multiple genes during the evolution of *Helicobacter pylori*. *PLoS Genetics* 2005; 1(4): e43.
- [58] Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA. a cancer journal for clinicians* 2011; 61(4): 212-236.

- [59] Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transition according to the Human Development Index (2008-2030): a population-based study. *Lancet Oncology* 2012; 13(8): 790-801.
- [60] World Health Organization. Global action against cancer. Global cancer control. WHO Library Cataloguing-in-Publication Data. Switzerland 2005. <http://www.who.int/cancer/media/en/GlobalActionCancerEnglfull.pdf> (accessed 01 december 2013).
- [61] Malfertheiner P, Bornschein J, Selgrad M. Role of *Helicobacter pylori* infection in gastric cancer pathogenesis: a chance for prevention. *Journal of Digestive Diseases* 2010; 11(1): 2-11.
- [62] Nardone G, Rocco A, Malfertheiner P. Review article: *Helicobacter pylori* and molecular events in precancerous gastric lesions. *Alimentary pharmacology & therapeutics* 2004; 20(3): 261-270.
- [63] Hoehnberger P, Gretscher S. Gastric cancer. *Lancet* 2003; 362(9380): 305-315.
- [64] Bowles MJ, Benjamin IC. ABC of the upper gastrointestinal tract. Cancer of the stomach and pancreas. *BMJ* 2001; 323(7326): 1413-1416.
- [65] Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W. Comparison of stomach cancer incidence and survival in four continents. *European Journal of Cancer* 2003; 39(11): 1603-1609.
- [66] Guerra MR, Gallo CVM, Mendonça GAS. The risk of cancer in Brazil: tendencies and recent epidemiologic studies. *Revista Brasileira de Cancerologia* 2005; 51(3): 227-234.
- [67] Ministério da Saúde. Instituto Nacional do Câncer José Alencar Gomes da Silva. Estimativa 2014 – Incidência de Câncer no Brasil. MS: <http://www2.inca.gov.br> (accessed 29 November 2013).
- [68] Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal type carcinoma. *Acta Pathologica et Microbiologica Scandinavica* 1975; 64: 31-49.
- [69] Sugiyama T, Asaka M. *Helicobacter pylori* infection and gastric cancer. *Medical Electron Microscopy* 2004; 37(3): 149-157.
- [70] Yoshimura T, Shimoyama T, Fukuda S, Tanaka M, Axon AT, Munakata A. Most gastric cancer occurs on the distal side of the endoscopic atrophic border. *Scandinavian Journal of Gastroenterology* 1999; 34(11): 1077-1081.
- [71] Polk DB; Peek Jr RM. *Helicobacter pylori*: gastric cancer and beyond. *Nature Reviews. Cancer* 2010; 10(6): 403-414.
- [72] Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. *Lancet* 1975; 2(7924): 58-60.

- [73] Correa P. A human model of gastric carcinogenesis. *Cancer Research* 1988; 48(13): 3554-3560.
- [74] Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – First American Cancer Society Award lecture on cancer epidemiology and prevention. *Cancer Research* 1992; 52(24): 6735-6740.
- [75] Correa P, Piazuelo MB. The gastric precancerous cascade. *Journal of Digestive Diseases* 2012; 13(1): 2-9.
- [76] Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P. Long term follow up of patients treated for *Helicobacter pylori* infection. *Gut* 2005; 54(11): 1536-1540.
- [77] Cheung TK, Xia HH, Wong BCY. *Helicobacter pylori* eradication for gastric cancer prevention. *Journal of Gastroenterology* 2007; 42(Suppl. 17): 10-15.
- [78] Yang Y, Deng CS, Peng JZ, Wong BC, Lam SK, Xia HH. Effect of *Helicobacter pylori* on apoptosis and apoptosis related genes in gastric cancer cells. *Molecular Pathology* 2003; 56(1): 19-24.
- [79] Kuipers EJ. Review article: relationship between *Helicobacter pylori*, atrophic gastritis and gastric cancer. *Alimentary pharmacology & therapeutics* 1998; 12(Suppl 1): 25-36.
- [80] Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, Sitas F. Association between infection with *Helicobacter pylori* and risk of gastric cancer: evidence from a prospective investigation. *BMJ* 1991; 302(6788): 1302-1305.
- [81] Danesh J. *Helicobacter pylori* infection and gastric cancer: systemic review of the epidemiological studies. *Alimentary pharmacology & therapeutics* 1999; 13(7): 851-856.
- [82] Herrera V, Parsonnet J. *Helicobacter pylori* and gastric adenocarcinoma. *Clinical Microbiology and Infection* 2009; 15(11): 971-976.
- [83] de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to *Helicobacter pylori* infection. *Helicobacter* 2007; 12(1): 1-15.
- [84] Correa P, Houghton J. Carcinogenesis of *Helicobacter pylori*. *Gastroenterology* 2007; 133(2): 659-672.
- [85] Filipe MI, Potet F, Bogomoletz WV, Dawson PA, Fabiani B, Chauveinc P, Fenzy A, Gazzard B, Goldfain D, Zeegen R. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. *Gut* 1985; 26(12): 1319-1326.
- [86] Rugge M, Correa P, Dixon MF, Haltori T, Leandro G, Lewin K, Riddeli RH, Sipponen P, Watanabe H. Gastric dysplasia: the Padova international classification. *The American journal of surgical pathology* 2000; 24(2): 167-176.

- [87] Lauwers GY, Srivastava A. Gastric preneoplastic lesions and epithelial dysplasia. *Gastroenterology clinics of North America* 2007; 36(4): 813-829.
- [88] Hirota WK, Zuckerman MJ, Adler DG, Davila RE, Egan J, Leighton JA, Qureshi WA, Rajan E, Fanelli R, Wheeler-Harbaugh J, Baron TH, Faigel DO. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. *Gastrointestinal Endoscopy* 2006; 63(4): 570-580.
- [89] Everett SM, Axon ATR. Early gastric cancer: disease or pseudo-disease? *Lancet* 1998; 351(9112): 1350-1352.
- [90] Goelz SE, Hamilton SR, Vogelstein B. Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. *Biochemical and Biophysical Research Communications* 1985; 130(1): 118-126.
- [91] Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science* 1988; 239(4839): 487-491.
- [92] Lage AP, Godfroid P, Fauconnier A, Burette A, Butzler JP, Bollen A, Glupczynski Y. Diagnosis of *Helicobacter pylori* infection by PCR: comparison with other invasive techniques and detection of *cagA* gene in gastric biopsy specimens. *Journal of Clinical Microbiology* 1995; 33(10): 2752-2756.
- [93] Atherton JC, Peek RM, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in *vacA*, the vacuolating cytotoxin gene of *Helicobacter pylori*. *Gastroenterology* 1997; 112(1): 92-97.
- [94] Atherton JC, Cover TL, Twells RJ, Morales MR, Hawkey CJ, Blaser MJ. Simple and accurate PCR-based system for typing vacuolating cytotoxin alleles of *Helicobacter pylori*. *Journal of Clinical Microbiology* 1999; 37(9): 2979-2982.
- [95] Thomazini CM, Pinheiro NA, Pardini MI, Naresse LE, Rodrigues MAM. Infecção por *Helicobacter pylori* e câncer gástrico: frequência de cepas patogênicas *cagA* e *vacA* em pacientes com câncer gástrico. *Jornal Brasileiro de Patologia e Medicina Laboratorial* 2006; 42(1): 25-30.
- [96] Faundez G, Troncoso M, Figueroa G. *cagA* and *vacA* in strains of *Helicobacter pylori* from ulcer and non-ulcerative dyspepsia patients. *BMC Gastroenterology* 2002; 2:20-24.
- [97] Mattar R, Marques SB, Monteiro MS, Santos AF, Iriya K, Carrilho FJ. *Helicobacter pylori* *cag* pathogenicity island genes: clinical relevance for peptic ulcer disease development in Brazil. *Journal of Medical Microbiology* 2007; 56(1): 9-14.
- [98] Foxman B, Riley L. Molecular Epidemiology: Focus on Infection. *American Journal of Epidemiology* 2001; 153(12): 1135-1141.
- [99] Nozaki K, Shimizu N, Inada K, Tsukamoto T, Inoue M, Kumagai T, Sugiyama A, Mizoshita T, Kaminishi M, Tatematsu M. Synergistic promoting effects of *Helicobacter*

pylori infection and high-salt diet on gastric carcinogenesis in Mongolian gerbils. Japanese Journal of Cancer Research 2002; 93(10): 1083-1089.

- [100] Humar B, Blair V, Charlton A, More H, Martin I, Guilford P, E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Research 2009; 69(5): 2050-2056.
- [101] Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Science 2008; 99(9): 1726-1733.
- [102] Suzuki H, Hibi T, Marshall BJ. *Helicobacter pylori*: present status and future prospects in Japan. Journal of Gastroenterology 2007; 42(1): 1-15.
- [103] Xia HH, Yu Wong BC, Talley NJ, Lam SK. Alternative and rescue treatment regimens for *Helicobacter pylori* eradication. Expert Opinion of Pharmacotherapy 2002; 3(9): 1301-1311.
- [104] Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of *Helicobacter pylori* screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996; 348(9021): 150-154.
- [105] Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of population-based *Helicobacter pylori* screening to prevent gastric cancer. Archives of Internal Medicine 1999; 159(2): 142-148.
- [106] Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Patel P et al. Cost-effectiveness of population screening for *Helicobacter pylori* in preventing gastric cancer and peptic ulcer disease, using simulation. Journal of Medical Screening 2003; 10(3): 148-156.
- [107] Fuccio L, Zagari RM, Minardi ME, Bazzoli F. Systematic review. *Helicobacter pylori* eradication for the prevention of gastric cancer. Alimentary Pharmacology & Therapeutics 2007; 25(2): 133-141.
- [108] Uemura N, Okamoto S, Yamamoto S, Matsumura M, Yamaguchi S, Yamakido M, Taniiyama K, Sasaki N, Schlemper RJ. *Helicobacter pylori* infection and the development of gastric cancer. New England Journal of Medicine 2001; 345(11): 784-789.
- [109] Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ. Factors predicting progression of gastric intestinal metaplasia. Results of a randomized trial on *Helicobacter pylori* eradication. Gut 2004; 53(9): 1244-1249.
- [110] Zhou L, Sung JJ, Lin S, Jin Z, Ding S, Huang X, Xia Z, Guo H, Liu J, Chao W. A five-year follow-up study on the pathological changes of gastric mucosa after *H. pylori* eradication. Chinese Medical Journal 2003; 116(1): 11-14.
- [111] Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-*Helicobacter pylori* therapy. Journal of the National Cancer Institute 2000; 92(23): 1881-1888.

- [112] Genta RM, Lew GM, Graham DY. Changes in the gastric mucosa following eradication of *Helicobacter pylori*. *Modern Pathology* 1993; 6(3): 281-289.
- [113] Ciok J, Dzieniszewski J, Lucer C. *Helicobacter pylori* eradication and antral intestinal metaplasia – two years follow-up study. *Journal of Physiology and Pharmacology* 1997; 48(Suppl. 4): 115-122.
- [114] Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G. Effect of *Helicobacter pylori* eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. *Cancer Epidemiology, Biomarkers & Prevention* 1997; 6(8): 639-642.
- [115] Kim N, Lim SH, Lee KH, Choi SE, Jung HC, Song IS, Kim CY. Long-term effects of *Helicobacter pylori* eradication on intestinal metaplasia in patients with duodenal and benign gastric ulcers. *Digestive Diseases and Sciences* 2000; 45(9): 1754-1762.
- [116] Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, Yokoyama T, Watanabe M. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom *Helicobacter pylori* was eradicated. *Annals of Internal Medicine* 2001; 134(5): 380-386.
- [117] Kokkola A, Sipponen P, Rautelin H, Härkönen M, Kosunen TU, Haaapiainen R, Puolakkainen P. The effect of *Helicobacter pylori* eradication on the natural course of atrophic gastritis with dysplasia. *Alimentary Pharmacology & Therapeutics* 2002; 16(3): 515-520.
- [118] Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, Sumii M, Tanaka S, Yoshihara M, Chayama K. *Helicobacter pylori* eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. *Alimentary Pharmacology & Therapeutics* 2002; 16(8): 1449-1456.
- [119] You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF Jr, Xu GW, Gail MH. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. *Journal of the National Cancer Institute* 2006; 98(14): 974-983.
- [120] Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Figueroa LS, Halperin D, Johnstone I, Parsonnet J. *Helicobacter pylori* eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. *Cancer Epidemiology, Biomarkers & Prevention* 2004; 13(1): 4-10.
- [121] Witteman EM, Mravunac M, Becx MJ, Hopman WP, Verschoor JS, Tytgat GN, de Koning RW. Improvement of gastric inflammation and resolution of epithelial damage one year after eradication of *Helicobacter pylori*. *Journal of Clinical Pathology* 1995; 48(3): 250-256.

- [122] Forbes GM, Warren JR, Glaser ME, Cullen DJ, Marshall BJ, Collins BJ. Long-term follow-up of gastric histology after *Helicobacter pylori* eradication. *Journal of Gastroenterology and Hepatology* 1996; 11(7): 670-673.
- [123] van der Hulst RW, van der Ende A, Dekker FW, Ten Kate FJ, Weel JF, Keller JJ, Kruijsing SP, Dankert J, Tytgat JN. Effect of *Helicobacter pylori* eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. *Gastroenterology* 1997; 113(1): 25-30.
- [124] Satoh K, Kimura K, Takimoto T, Kihira K. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of *Helicobacter pylori*. *Helicobacter* 1998; 3(4): 236-240.
- [125] Kyzekova J, Mour J. The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and *Helicobacter pylori* infection. Prospective randomized intervention study. *Hepatogastroenterology* 1999; 46(27): 2048-2056.
- [126] Annibale B, Aprile MR, D'Ambra G, Caruana P, Bordi C, Delle Fave G. Cure of *Helicobacter pylori* infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. *Alimentary Pharmacology & Therapeutics* 2000; 14(5): 625-634.
- [127] Sung JJ, Lin SR, Ching IY, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT, Yeung CK, Chao W, Chung SC. Atrophy and intestinal metaplasia one year after cure of *H. pylori* infection: a prospective, randomized study. *Gastroenterology* 2000; 119(1): 7-14.
- [128] Kamada T, Haruma K, Hata J, Kusunoki H, Sasaki A, Ito M, Tanaka S, Yoshihara M. The long-term effect of *Helicobacter pylori* eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. *Alimentary Pharmacology & Therapeutics* 2003; 18(2): 245-252.
- [129] Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, Festen HP, Dent J, Zeitoun P, Havu N, Lamm M, Walan A. Cure of *Helicobacter pylori* infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. *Gut* 2004; 53(1): 12-20.
- [130] Ruiz B, Garay J, Correa P, Fontham ET, Bravo JC, Bravo LE, Realpe JL, Mera R. Morphometric evaluation of gastric antral atrophy: improvement after cure of *Helicobacter pylori* infection. *American Journal of Gastroenterology* 2001; 96(12): 3281-3287.
- [131] Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M, Japan Gast Study Group. Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. *Lancet* 2008; 372(9636): 350-352.

- [132] Ito M, Takata S, Tatsugami M, Wada Y, Imagawa S, Matsumoto Y, Takamura A, Kitamura S, Matsuo T, Tanaka S, Haruma K, Chayama K. Clinical prevention of gastric cancer by *Helicobacter pylori* eradication therapy: a systematic review. *Journal of Gastroenterology* 2009; 44(5): 365-371.
- [133] Takata S, Ito M, Yoshihara M, Tanaka S, Imagawa S, Haruma K, Chayama K. Host factors contributing to the discovery of gastric cancer after successful eradication therapy of *Helicobacter pylori*: preliminary report. *Journal of Gastroenterology and Hepatology* 2007; 22(4): 571-576.
- [134] Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS, China Gastric Cancer Study Group. *Helicobacter pylori* eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA* 2004; 291(2): 187-194.
- [135] Kabir S. Effect of *Helicobacter pylori* eradication on incidence of gastric cancer in human and animal models: underlying biochemical and molecular events. *Helicobacter* 2004; 14(3): 159-171.
- [136] Rogers AB, Fox JG. Inflammation and Cancer. Rodent models of infectious gastrointestinal and liver cancer. *American Journal of Physiology. Gastrointestinal and Liver Physiology* 2004; 286(3): G361-G366.
- [137] Romero-Gallo J, Harris EJ, Krishna U, Washington MK, Perez-Perez GI, Peek Jr RM. Effect of *Helicobacter pylori* eradication on gastric carcinogenesis. *Laboratory Investigation* 2008; 88(3): 328-336.
- [138] Oda T, Murakami K, Nishizono A, Kodama M, Nasu M, Fujioka T. Long-term *Helicobacter pylori* infection in Japanese monkeys induces atrophic gastritis and accumulation of mutations in the *p53* tumor suppressor gene. *Helicobacter* 2002; 7(3): 143-151.
- [139] Hirayama F, Takagi S, Kusuhara H, Iwao E, Yokoyama Y, Ykeda Y. Induction of gastric ulcer and intestinal metaplasia in mongolian gerbils infected with *Helicobacter pylori*. *Journal of Gastroenterology* 1996; 31(5): 755-757.
- [140] Shimizu N, Inada K, Nakanishi H, Tsukamoto T, Ikehara Y, Kaminishi M, Kuramoto S, Sugiyama A, Katsuyama T, Tatematsu M. *Helicobacter pylori* infection enhances glandular stomach carcinogenesis in Mongolian gerbils treated with chemical carcinogens. *Carcinogenesis* 1999; 20(4): 669-676.
- [141] Sugiyama A, Maruta F, Ikeno T, Ishida K, Kawasaki S, Katsuyama T, Shimizu N, Tatematsu M. *Helicobacter pylori* infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil. *Cancer Research* 1998; 58(10): 2067-2069.
- [142] Tokieda M, Honda S, Fujioka T, Nasu M. Effect of *Helicobacter pylori* infection on the N-methyl-N-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in Mongolian gerbils. *Carcinogenesis* 1999; 20(7): 1261-1266.

- [143] Franco AT, Israel DA, Washington MK, Krishna U, Fox JG, Rogers AB, Neish AS, Collier-Hyams L, Perez-Perez GI, Hatakeyama M, Whitehead R, Gaus K, O'Brien DP, Romero-Gallo J, Peek RM Jr. Activation of beta-catenin by carcinogenic *Helicobacter pylori*. *Proceedings of the National Academy of Sciences of the United States of America* 2005; 102(30): 10646-10651.
- [144] Cai X, Carlson J, Stoicov C, Li H, Wang TC, Houghton J. *Helicobacter felis* eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. *Gastroenterology* 2005; 128(7): 1937-1952.
- [145] Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, Hosokawa K, Shimoda T, Yoshida S. Endoscopic mucosal resection for treatment of early gastric cancer. *Gut* 2001; 48(2): 225-229.

